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Background. Peritoneal cancer treatment aims to prolong survival, but preserving Quality of Life (QoL) under treatment is also a
priority. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel minimally invasive repeatable treatment modality.
The aim of the present study was to assess QoL in our cohort of PIPAC patients. Methods. Analysis of all consecutive patients
included from the start of PIPAC program (January 2015). QoL (0–100: optimal) and symptoms (no symptom: 0–100) were
measured prospectively before and after every PIPAC procedure using EORTCQLQ-C30. Results. Forty-two patients (M : F = 8 : 34,
median age 66 (59–73) years) had 91 PIPAC procedures in total (1 : 4x, 17 : 3x, 12 : 2x, and 12 : 1x). Before first PIPAC, baseline QoL
was measured as median of 66±2.64. Prominent complaints were fatigue (32±4.3) and digestive symptoms as diarrhea (17±3.75),
constipation (17 ± 4.13), and nausea (7 ± 2.54). Overall Quality of Life was 64 ± 3.75 after PIPAC#1 (𝑝 = 0.57), 61 ± 4.76 after
PIPAC#2 (𝑝 = 0.89), and 70 ± 6.67 after PIPAC#3 (𝑝 = 0.58). Fatigue symptom score was 44 ± 4.86 after PIPAC#1 and 47 ± 6.69
and 34 ± 7.85 after second and third applications, respectively (𝑝 = 0.40). Diarrhea (𝑝 = 0.31), constipation (𝑝 = 0.76), and nausea
(𝑝 = 0.66) did not change significantly under PIPAC treatment. Conclusion. PIPAC treatment of peritoneal carcinomatosis had no
negative impact on patients’ overall QoL and its components or on main symptoms. This study was registered online on Research
Registry (UIN: 1608).
1. Introduction
Requirements for optimal oncological treatment include
oncological efficacy (tumor response, survival) but also low
toxicity, few side effects, and no negative impact on Quality
of Life (QoL). Peritoneal carcinomatosis (PC) remains a
particular challenge with sparse treatment options but high
potential for side effects and complications [1, 2].
The effect of systemic chemotherapy remains limited
on the peritoneum due to low penetration and relative
resistance of peritoneal nodules. Combining several active
agents has increased efficacy but was also associated with
considerable risk for side effects with negative impact onQoL
[3]. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
overcomes some of the pharmacokinetic limitations and
improves survival in selected patients [4, 5] at the price
of high morbimortality and a negative impact on QoL for
months after the procedure [6].
Intraperitoneal Aerosol Chemotherapy (PIPAC) was
developed to disperse the active agents inside the peritoneal
cavity by laparoscopy without tumor debulking, thus allow-
ing for repeated treatments [7–9]. The few available studies
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Figure 1: Treatment algorithm for Pressurized Intraperitoneal
Aerosol Chemotherapy (PIPAC). PIPAC treatment was scheduled
as repeated application (3x) at 6-week intervals. Thoracoabdominal
computed tomography (CT) was performed 4 weeks prior to
PIPAC#1, between PIPAC#2 and PIPAC#3, and after the completion
of intraperitoneal treatment to search for extraperitoneal disease.
Quality of Life (QoL) was systematically assessed (EORTC QLQ-
C30) during every patient encounter: in outpatient consultation,
before surgery, and at discharge.
reported encouraging objective tumor response of 50–86%
and only little toxicity in patients with therapy-refractory PC
of various origins [10–12]. Only one study reported on QoL
under PIPAC treatment so far [13].
The present analysis was performed to evaluate QoL and
symptoms under PIPAC treatment in a consecutive cohort of
patients with PC.
2. Methods
This study included all consecutive patients treated by PIPAC
from January 2015 until April 2016. All patients were dis-
cussed in the setting of a multidisciplinary tumor board
to determine the best treatment option for each patient.
PIPAC was considered only in patients with chemoresistant
isolated peritoneal carcinomatosis who were not eligible for
cytoreductive surgery (CRS) and Hyperthermic Intraperi-
toneal Chemotherapy (HIPEC) due to medical or surgical
contraindications. The study was approved by the Institu-
tional Review Board (Number 2016-00274) and all patients
provided written consent prior to surgery. STROBE criteria
(http://strobe-statement.org/) were followed for reporting of
the study (http://www.researchregistry.com/; UIN: 1608).
2.1. PIPAC Procedure and Treatment Algorithm. Surgical
setup, treatment regimens, and safety checklist were adopted
from recommendations by Solaß et al. [9, 17]. Three PIPAC
treatments were scheduled at 6-week intervals upon decision
of the multidisciplinary tumor board (Figure 1). Systemat-
ically, thoracoabdominal computed tomography (CT) was
performed not exceeding four weeks prior to first PIPAC
and between PIPAC#2 and PIPAC#3 to actively rule out
extraperitoneal disease. A third CT was scheduled 2 months
after the completed 3 PIPAC cycles. Every patient was seen
in outpatient consultation 4 weeks after PIPAC treatment for
monitoring of complications and evaluation of contraindica-
tions to proceed with further PIPAC. QoL assessment was
performed before surgery, at discharge, and every time when
the patient was seen in outpatient consultation (Figure 1).
2.2. Assessment of Quality of Life and Symptoms. Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) generic questionnaire QLQ-C30 (version 3.0) was
used to measure QoL and symptoms [14, 18]. QLQ-C30
is a 30-question self-administered questionnaire inquiring
about global health status, 9 individual symptoms, and 5
functional scales. Validated versionswere provided in French,
English, Italian, and German.The EORTCQLQ-C30 scoring
manual was followed in terms of scoring QoL data and with
regard to missing answers [19]. For statistical analysis, the
30 scores were linearly converted to a 0–100 scale according
to EORTC recommendations [19]. Of note, high functional
scores indicate a high level of function (optimum: 100), while
high symptom scores represented high degree of symptoms
(optimum: 0). A mean difference of ±5 was considered to be
of no clinical relevance for the patient, while ±5–10 and ±10–
20 points represented small and modest clinical differences,
respectively [15].
2.3. Data Management. Pertinent demographic and surgical
datawas prospectively recorded in coded form in a computer-
ized data base (secuTrial, IAS GmbH, Berlin). Performance
status was assessed according to the Eastern Cooperative
Oncology Group (ECOG) [20]. Intraoperative data included
peritoneal cancer index (PCI) [16], ascites (mL), adhesiolysis,
and operative time (min). Postoperative hospital stay and 30-
day complications (Clavien classification [21]) were reported.
2.4. Predefined Subgroup Analyses. Overall QoL under
PIPAC treatment was compared between patients with PC of
gynecological versus digestive origin to detect potential dif-
ferences between those different patient groups and entities.
Reaction to treatment and side effects might be different
after first application as compared with consecutive adminis-
tration. Further, cumulative toxicitymight decrease tolerance
to repeated application. Therefore, QoL and symptoms were
analyzed separately for PIPAC#1 as compared to repeated
PIPAC procedures.
A possible direct relationship was assessed between
higher intraperitoneal tumor load (measured by PCI) and
preoperative QoL. And finally, the hypothesis has tested
whether low baselineQoLwas correlatedwith longer hospital
stay after PIPAC treatment.
2.5. Statistical Analysis and Interpretation. Continuous vari-
ables were presented asmeanwith standard error of themean
(SEM) or median with range or interquartile range (IQR) as
appropriate. Student’s 𝑡-test and Mann–Whitney 𝑈 test were
used for statistical comparisons depending on the distribu-
tion. Categorical variables were reported as frequencies (%)
and compared with chi-square test. Statistical correlations
were tested by use of Spearman’s rank correlation. A 𝑝 value
< 0.05 was considered to be statistically significant in all
tests. Statistical analyses were performed and figures were
produced with SPSS v20 statistical software (Chicago, IL,
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Table 1: Baseline demographics and surgical details of patients treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).
All patients (𝑛 = 42) GYN (𝑛 = 21) Digestive (𝑛 = 21) 𝑝 value
Demographics
Median age (years) 66 (59–73) 67 (63–74) 62 (55–72) 0.193
Gender (male) 8 (19%) — 8 —
Median BMI (kg/m2) 22.5 (20–25) 23 (21–28) 22 (19–25) 0.116
BMI < 18.5 kg/m2 2 (5%) 0 2 —
ECOG (0-1) 36 (86%) 20 (95%) 76 (90%) 0.077
All PIPAC (𝑛 = 91) GYN (𝑛 = 51) Digestive (𝑛 = 40) 𝑝 value
Intra-OP findings
PCI 10 (5–17) 9 (4–14) 15 (7–19) 0.002
Ascites (mL) 50 (0–4000) 0 (0–300) 50 (0–4000) 0.034
Adhesions 15 (16%) 9 (18%) 6 (15%) 0.735
Operation time (min) 94 (89–108) 91 (87–97) 100 (92–117) 0.002
Median (IQR) or number of (%) as appropriate. Statistical significance (𝑝 < 0.05) is highlighted in bold.
BMI: Body Mass Index; ECOG: Eastern Cooperative Oncology Group performance status [20]; PCI: Peritoneal Cancer Index [16].
USA) and GraphPad Prism 7 (GraphPad Software, Inc., La
Jolla, CA, USA).
3. Results
Forty-two consecutive patients were included in the present
analysis as detailed in Table 1. Indication was carcinomatosis
of gynecological origin in 21 patients. The digestive group
included 14 patients with PC of colorectal and 3 of gastric
origin (1 each for small bowel, appendicular, pseudomyxoma,
and mesothelioma). One out of forty-two patients (2%)
had combined systemic chemotherapy. Overall, 91 PIPAC
procedures were performed in 42 patients (18 :≥3, 12 : 2,
and 12 : 1). Overall complication rate was 8.8% and median
hospital stay was 3 (range 1–20).
3.1. Quality of Life and Symptoms during PIPAC Treatment.
Overall QoL score was 66 ± 2.6 at baseline before the
start of PIPAC treatment. QoL scores during the treatments
cycles are displayed in Figure 2(a). QoL was not significantly
different before and after PIPAC#1, PIPAC#2, and PIPAC#3,
respectively, and the threshold for small or moderate clini-
cally relevant difference was not reached at any time point
(Figure 2(b)). Similarly, no significant changes were noted
under PIPAC treatment for the QoL components cognitive,
physical, emotional, role, and social functioning; individual
curves are provided as in Figure 3.
OverallQoLwas separately analyzed in gynecological and
digestive patients (Figure 4). The latter group tended to have
lower scores throughout the treatment coursewith significant
differences after PIPAC#1 (discharge: 𝑝 = 0.03; 4 weeks: 𝑝 =
0.02) and after PIPAC#2 (discharge: 𝑝 = 0.01).
Prominent complaints at baseline were fatigue (32 ± 4.3)
and the digestive symptoms diarrhea (17 ± 3.4), constipation
(17 ± 4.1), and nausea (7 ± 2.5). Digestive symptoms before
and after PIPAC are detailed for 1st, 2nd, and 3rd applications.
Nausea/vomiting increased transitorily after PIPAC#1 (𝑝 =
0.03), just reaching the defined threshold for a small clinically
relevant difference; no significant increase was present after
PIPAC#2 and PIPAC#3, respectively (Figure 5(a)). For the
symptoms appetite loss, constipation, and diarrhea, nonsignif-
icant variation was noted in both directions (Figures 5(b),
5(c), and 5(d)). Nondigestive symptoms insomnia, fatigue,
pain, and dyspnea did not show significant changes through-
out PIPAC treatment (Figure 6).
3.2. QoL and Symptoms after First and Repeated PIPAC.
Change of overall QoL (Δ before − after) was small and
nonsignificant for both 1st and repeated PIPAC procedures
(𝑝 = 0.388) as shown in Figure 7. Performing similar anal-
yses for digestive symptoms, there was a significantly higher
symptom score for constipation after PIPAC#1 as compared
to repeated PIPAC (𝑝 = 0.030), while no difference was
measured with regard to nausea/vomiting, appetite loss, and
diarrhea (Figures 8(a), 8(b), 8(c), and 8(d)).
3.3. Correlation between QoL, Tumor Load, and Hospital Stay
(Figure 9). There was no statistical correlation measured
between intraperitoneal tumor load (PCI) and preoperative
overall QoL (𝜌 = −0.169, 𝑝 = 0.122). Higher preoperative
QoL score was associated with shorter postoperative LoS
(days) (𝜌 = −0.213, 𝑝 = 0.05).
4. Discussion
PIPAC had no negative impact on patients’ overall QoL and
its components or on main symptoms. First and repetitive
PIPAC application was equally well tolerated. Baseline QoL
was good in patients with peritoneal disease and independent
of intraperitoneal tumor load.
Overall QoL at baseline before start of PIPAC treatment
was surprisingly high in the present cohort of patients with
peritoneal carcinomatosis. As comparison, a control group of
16,151 healthy citizens had a significantly higher QoL score
than this cohort (Figure 10) [22]. However, the observed
absolute difference between both groups was marginal in
terms of clinical relevance according to Osoba et al. [15].
Furthermore, there was no worse QoL in PIPAC patients
with high intraperitoneal tumor load (assessed by PCI). The
only difference was that patients with better overall QoL
scores at baseline had a significant shorter hospital stay.
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Figure 2: Quality of Life (QoL) under Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatment. Overall Quality of Life (QoL:
EORTC QLQ-C30 [14]) under PIPAC treatment is displayed (mean ± SEM). (a) No statistically significant difference (𝑝 < 0.05) was found
when QoL was compared before and after different PIPAC applications (a, b). The dotted lines (b) represent the thresholds for small (SCD)
and moderate clinically relevant differences (MCD), respectively [15].
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Figure 3: Cognitive, physical, emotional, role, and social functioning under Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).
Quality of Life (QoL: EORTC QLQ-C30 [14]) components under PIPAC treatment (mean ± SEM). No significant difference (𝑝 < 0.05) was
found when QoL was compared before and after different PIPAC applications (ns—not significant).
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Figure 4: Quality of Life (QoL) under Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in patients with gynecological versus
digestive malignancies. Overall Quality of Life (QoL: EORTC QLQ-C30 [14]) is displayed as mean ± SEM. ∗ indicates statistical significance
(𝑝 < 0.05).
These findings confirm two reports from the German PIPAC
pioneer group. Tempfer reported in a phase II study on
ovarian carcinomatosis patients a baseline global physical
health score of 52.0 with improvements in QoL scores and
symptoms under PIPAC treatment [11]. In the second study,
Odendahl et al. assessed QoL and symptoms in a mixed
cohort of PIPACpatients [13]. In the 48 reported patientswith
repeated PIPAC treatment, baseline global physical score was
astonishingly high with 82 points. This score was not only
higher than the baseline score of our own cohort but com-
pared also favorably with the benchmark QoL scores of the
general population cited above [22]. Under PIPAC treatment,
QoL and symptoms remained unchanged in the Odendahl
et al. study [13] as it was the case in our present series.
There are two important differences between the two studies.
First, 66 out of 114 eligible patients of the German cohort
had to be excluded for missing QoL questionnaires [13].
QoL and symptoms of over the half of their cohort remain
therefore unknown, while QoL assessment was complete in
our present series. Second, QoL assessment was done only
the day before surgery in the two German studies [11, 13].
Therefore, transitory deterioration might have been missed
given the long washout period of about 6 weeks between
PIPAC applications. For these reasons, in the present study,
it was decided to add more time points to measure QoL and
symptoms in between applications, namely, immediately at
discharge day and 4weeks after discharge. As suspected, some
worsening of QoL and symptoms was observed at discharge
(Figures 2(a) and 3), which was in most patients only 2-3
days after PIPAC treatment. However, those deviations from
baseline were minimal and transitory.
It is important to assess QoL and symptoms under
oncological treatment because both disease and treatment
may have negative impact. A recent prospective multicenter
longitudinal study evaluated results of systemic palliative
chemotherapy in end-stage cancer patients. The authors
observed no survival benefit and no improvements of QoL
for patients with moderate and poor performance status
(ECOG = 2, 3) at baseline. In patients with good baseline
performance status (ECOG = 1), QoL was even signifi-
cantly worse under systemic palliative chemotherapy [6].
In a secondary analysis, the authors compared patients
receiving palliative chemotherapy versus best supportive care
employing propensity score weighted adjustment. Patients
under palliative systemic chemotherapy had a higher risk for
cardiopulmonary resuscitation, invasive ventilation, and late
hospice referrals. Patients without treatment had the same
survival times but a significantly higher chance of dying in
their preferred place instead of in the intensive care unit [23].
In the management of peritoneal carcinomatosis, HIPEC
has a curative intent while PIPAC is considered palliation,
since no data on long-term outcome after PIPAC is available
so far. Therefore, their respective indications are different. In
this context, it is important to weigh the expected survival
benefits against morbid-mortality and impact on QoL. Two
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Figure 5: Digestive symptoms under Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Digestive symptoms were assessed by use
of EORTC QLQ-C30 [14] and displayed as difference (Δ before − after). Statistical significance (𝑝 < 0.05) is highlighted (bold) and small
(SCD) and modest (MCD) clinically relevant differences [15] are illustrated by dashed lines.
recent studies reported decreased QoL and increased symp-
toms 6–12 months after HIPEC treatment. And this was also
observed in patients without postoperative complications
[24, 25].
Good tolerance profile and QoL under PIPAC treatment
allowed assessing bidirectional regimens combining systemic
and intraperitoneal PIPAC treatment. Safety, tolerance, and
QoL were still acceptable under bidirectional treatment that
might offer a chance for downstaging and secondary CRS +
HIPEC in selected patients [12, 26–28].
Concerning efficacy, first results of the pioneer center
from Herne, Germany, were encouraging, but longer follow-
up periods are required for assessment of oncological out-
comes [11, 12, 28]. Furthermore, independent confirmation of
histological regression under PIPAC treatment in a standard-
ized way is needed. Future prospective studies should present
histological results in a systematic way using a recently
published tumor regression score [29].
Main limitations of this study are its small and hetero-
geneous patient cohort and its retrospective design. On the
other hand, QoL assessment was prospectively performed in
all consecutive patients from the beginning of the PIPAC
program and no patient was excluded from this analysis.
Furthermore, PIPAC procedure and treatment algorithms
were standardized.
In summary, this study suggests that PIPAC had no
negative impact on QoL in patients with peritoneal carci-
nomatosis. Digestive and nondigestive symptoms remained
unchanged after a first PIPAC application but also after
repeated treatments. Prospective evaluation of histological
response rates and survival times under PIPAC treatment is
underway.
Abbreviations
PC: Peritoneal carcinomatosis
QoL: Quality of Life
PIPAC: Pressurized Intraperitoneal Aerosol
Chemotherapy
PCI: Peritoneal Carcinomatosis Index.
Gastroenterology Research and Practice 7
4
w
ns nsns
ns
100
80
60
40
20
0
O
ut
pa
tie
nt
PI
PA
C 
#1
PI
PA
C 
#2
PI
PA
C 
#3
D
isc
ha
rg
e
4
w
D
isc
ha
rg
e
4
w
D
isc
ha
rg
e
Fatigue
Insomnia
(a)
4
w
ns nsns
ns
100
80
60
40
20
0
O
ut
pa
tie
nt
PI
PA
C 
#1
PI
PA
C 
#2
PI
PA
C 
#3
D
isc
ha
rg
e
4
w
D
isc
ha
rg
e
4
w
D
isc
ha
rg
e
Pain
Dyspnea
(b)
Figure 6: Nondigestive symptoms under Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Nondigestive symptoms (QoL:
EORTC QLQ-C30 [14]) under PIPAC treatment (mean ± SEM). No significant difference (𝑝 < 0.05) was found when QoL was compared
before and after different PIPAC applications (ns—not significant).
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Figure 7: Quality of Life (QoL) change after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): 1st application versus repeated
procedures. Quality of Life (QoL: EORTCQLQ-C30 [14]) asΔ before− afterwas compared for PIPAC#1 versus repeated procedures. Statistical
significance: 𝑝 < 0.05. ns—not significant. SCD: small clinically relevant difference, MCD: modest MCD clinically relevant difference [15].
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Figure 8: Symptom change after Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): 1st application versus repeated procedures.
Digestive symptoms were assessed by use of EORTC QLQ-C30 [14] and displayed as difference (Δ before − after). ∗Statistical significance
(𝑝 < 0.05). SCD: small clinically relevant difference, MCD: moderate clinically relevant difference [15].
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Figure 9: Quality of Life, tumor load, and hospital stay. Overall QoL was plotted against the extent of peritoneal disease (measured by the
Peritoneal Cancer Index (PCI) [16]) (a) and length of hospital stay (LoS) (b).
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Figure 10: Overall Quality of Life (QoL) in PIPAC patients (Lau-
sanne cohort) as compared with the general population. Overall
QoL was compared by use of EORTC QLQ-C30 [14] for the
Lausanne PIPAC cohort versus a European cohort of 16,151 healthy
citizens (general population).The control group had a slightly better
QoL score that was statistically significant but of small clinical
relevance (<10%) according to Osoba et al. [15].
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